Skip to main content

Table 4 Hepatic dysfunction occurrence rates based ons Rituximab administration

From: Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma

Use of rituximab Patients with hepatic dysfunction (N = 40) (49.4%) Patients without hepatic dysfunction (N = 41) (50.6%) p-value
Yes 13 (32.5) 14(34.1) 0.88
No 27(67.5) 27(65.9)